Evaluation of Selected Indicators of Apoptosis in Patients with Thyroid Tumors

• Authors: Krzysztof Kołomecki , Piotr Maciaszczyk , Henryk Stępień , Jacek Cywiński , Justyna Cielecka , Tomasz Stępień , Krzysztof Kuzdak
• Languages of publication: EN

Abstracts

EN

The aim of the study. Estimatation of p53 protein and soluble FasL ligand level concentration in serum of patients with benign and malignant primary follicular thyroid tumors as indicators of apoptosis and evaluation of their usefulness for early diagnosis of thyroid tumors.Material and methods. 42 patients were qualified for the study. 28 patients were diagnosed with follicular neoplasm (NF) in preoperative fine-needle biopsy. The final verification was postoperative histopathology. Control group consisted of 14 patients with euthyroid goiter, with no cancerous cells detected in cytologic examination. All patients underwent surgical procedures. Levels of p53 and sFasL were marked on the day of admission, before surgery. Destinationes were made in the serum using the ELISA immunoenzymatic method. Obtained data underwent computer statistical analysis.Results. The analysis revealed significantly higher sFasL and p53 concentration in blood of patients with follicular thyroid cancer in comparison with the control group. Similarly, p53 serum level was significantly higher in case of patients with benign thyroid adenoma than in the control group. Comparison between p53 and sFasL serum level in cases of patients with follicular cancer and follicular adenoma showed statistically higher sFasL blood concentration in cases of patients with follicular cancer; there was no statistically significant connection in case of p53 concentration.Conclusions. 1. sFasL and p53 serum concentration are significantly higher in patients with follicular thyroid cancer than in the control group. 2.The p53 serum concentration is significantly higher in cases of all patients with benign thyroid adenoma than in the control group. There was no such correlation for sFasL concentration. 3. sFasL serum concentration is significantly higher in cases of patients with follicular thyroid cancer than in patients with benign thyroid adenoma. There was no such correlation with serum levels of p53.

Keywords

EN

apoptosis; p53; sFasL; follicular thyroid cancer

• Publisher: Index Copernicus International
• Journal: Polish Journal of Surgery
• Year: 2007
• Volume: 79
• Issue: 2
• Pages: 85-91

Dates

published

1 - 2 - 2007

online

24 - 9 - 2007

Contributors

author

Krzysztof Kołomecki

• Department of Surgery, Ministry of Internal Affairs and Administration Hospital, Łdź

author

Piotr Maciaszczyk

• Department of Surgery, Ministry of Internal Affairs and Administration Hospital, Łdź

author

Henryk Stępień

• Clinic of Endocrinology, Medical University, Łdź

author

Jacek Cywiński

• Department of Surgery, Ministry of Internal Affairs and Administration Hospital, Łdź

author

Justyna Cielecka

• Department of Surgery, Ministry of Internal Affairs and Administration Hospital, Łdź

author

Tomasz Stępień

• Clinic of General and Endocrinological Surgery, Medical University, Łdź

author

Krzysztof Kuzdak

• Clinic of General and Endocrinological Surgery, Medical University, Łdź

References

• Lange D, Sporny S, Sygut J i wsp.: Kryteria różnicowania między rakiem brodawkowatym a pęcherzykowym tarczycy - pierwsze wnioski z badania wieloośrodkowego. Wiad Lek 2001; 54: 1: 42-53.
• Koźlak J, Duś D: Udział receptora Fas i jego liganda FasL w progresji nowotworowej? J Oncol 2002; 52.
• Szala S: Swoista indukcja apoptozy w komórkach nowotworowych. Nowotwory 2000; 50(2): 111-21.
• Vaux DL, Korsmeyer J: Cell death in development. Cell 1999; 96: 245-54.
• Thornberry NA, Lazebnik Y: Caspases: enemies within. Science 1998; 281: 1312-16.
• Wolf BB, Green DR: Suicidal tendencies: apoptotic cell death by caspase family protenases. J Biol Chem 1999; 274: 20049-52.
• Podack ER: How to induce involuntary suicide: the need for dipeptidyl peptidase I. Proc Natl Acad Sci USA 1999; 96: 8812-14.
• Ashkenazi A, Dixit VM: Death receptors: signaling and modulation. Science 1998; 281: 1305-08.[WoS]
• Daniel PT, Wieder T, Sturm I et al.: The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia 2001; 15: 1022-32.
• Midis GP, Shen Y, Owe- Schaub LB: Elevated soluble Fas (sFas) levels in nonhematopoietic malignancy. Cancer Res 1 in nonhematopoietic malignancy. Cancer Res 1996; 56: 3870-74.
• Tanaka M, Toshimitsu L, Adachi M et al.: Downregulation of Fas ligand by shedding. Nature Med 1998; 4: 31-36.
• Evan G, Littlewood T: A matter of life and cell death. Science 1998; 94: 695-98.
• Bennett M, Macdonald K, Chan SW et al.: Cell surface trafficking of Fas: a rapid mechanism of P53-mediated apoptosis. Science 1998; 282: 290-93.
• Green DR: Apoptotic pathways: the roads to ruin. Cell 1998; 281: 695-98.
• Rybiński K, Narębski J, Pomorski L: Współczesne leczenie chirurgiczne raka tarczycy. Endokrynol Pol 1999; 50(2): 63-72.
• O'Connell J, O'Sullivan GC, Collins JK et al.: The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184(3): 1075-82.
• Hahne M, Rimoldi D, Schroter M et al.: Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274: 1363-66.
• Strand S, Hofmann WJ, Hug H et al.: Lympocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nature Med 1996; 1361-66.
• Higaki K, Yano H, Kojiro M: Fas antigen expression and its relationship with apoptosis in human hepatocellular carcinoma and noncancerous tissues. Am J Pathol 1996; 149: 429-37.
• Hohlbaum AM, Moes S, Rothstein AM: Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med 2000; 191: 1209-20.
• Konno R, Takano T, Sato S et al.: Serum soluble Fas level as a prognostic factor in patients with gynecological malignancies. Clin Cancer Res 2000; 6: 3576-80.
• Shudo K, Kinoshita K, Imamura R et al.: The membrane- bound but not the soluble form of human Fas ligand is responsible for its inflammatory activity. Eur J Immunol 2001; 31: 2504-11.
• Hosaka N, Oyaizu et al.: Membrane and soluble forms of Fas (CD95) and Fas ligand in peripheral blood mononuclear cells and in plasma from human immunodeficiency virus-infected persons. J Infect Dis 1998; 178(4): 1030-39.
• Nakamoto K, Kaneko S et al.: Inhibition of peripheral blood lympocyte apoptosis by soluble fas ligand in patients with hepatocellular carcinoma. Oncol Rep 1999; 6(4): 733-39.
• Taieb J, Mathurin P et al.: Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease. Lancet 1998 27; 351(9120): 1930-31.
• Shiota G, Oyama K et al.: Clinical significance of serum soluble Fas ligand in patients with acute self-limited and fulminant hepatitis. Res Commun Mol Pharmacol 1998; 101(1): 3-12.
• Sano H, Asano K et al.: Plasma soluble fas and soluble fas ligand in chronic glomerulonephritis. Nephron 1998; 80(2): 153-61.
• Ichikura T, Majima T, Uchida T et al.: Plasma soluble ligand concentration: decrease in elderly men and increase in patients with gastric carinoma. Oncol Rep 2001; 8: 311-14.
• Schmitt CA, Lowe SW: Apoptosis and therapy. J Pathol 1999; 187: 127-37.
• Mulder JW et al.: p53 and CD4 as clinical markers of tumours progression in colorectal carcinogenesis. Histochem J 1997; 29(6): 439-52.
• Khan S et al.: Diagnostic value of p53 immuno-histochemistry in Barrett's esophagus: an endoscopic study. Pathology 1998; 30(2): 136-40.[Crossref]
• Harris CC: p53: at the crossroads of molecular carcinogenesis and molecular epidemiology. J Investig Dermatol Symp Proc 1996; 1(2): 115-18.
• Gorczyca W, Melamed MR, Darzynkiewicz Z: Programowana śmierć komórek (apoptoza). Pat Pol 1993; 44(3): 113-19.

Identifiers

DOI

10.2478/v10035-007-0014-x